-continued

glycerol palmitostearate	mg	5
amphiphilic matrix component: soy lecithin	mg	7
hydrophilic matrix components: xylitol	mg	168
maltodextrins	mg	150
hydroxypropylmethylcellulose	mg	20
adjuvants: aspartame	mg	5
flavour	mg	5
colloidal silica	mg	5
magnesium stearate	mg	5

400 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the irritating taste of the active ingredient.

Example M

Operating as described in Example I, but with the following components:

active ingredient: chlorhexidine	mg	2.5
lipophilic/inert matrix component: cetyl alcohol	mg	0.5
glycerol palmitostearate	mg	0.5
amphiphilic matrix component: diethylene glycol monoethyl ether	mg	0.3
hydrophilic matrix components: xylitol	mg	38
maltodextrins	mg	96
hydroxypropyl methylcellulose	mg	10
adjuvants: aspartame	mg	3
flavour	mg	5
colloidal silica	mg	2
magnesium stearate	mg	2

150 mg unitary weight tablets are obtained, which undergo progressive erosion upon buccal administration, and effectively mask the irritating taste of the active ingredient.

Example N

One Kg of Nimesulide is placed in a high rate granulator, pre-heated to about 70°, together with g 125 of cetyl alcohol: the mixture is kneaded for about 15 minutes and stirred while decreasing temperature to about 30° C., then added with g 30 of lecithin. The resulting matrix is then extruded through a metallic screen of suitable size and mixed with 2.415 kg of lactose, 1.0 kg of maltodextrins, 50 g of hydroxypropyl methylcellulose, 50 g of colloidal silica, 40 g of aspartame, 150 g of citric acid, 75 g of flavor and 65 g of magnesium stearate. The final mixture is tableted to about 500 mg tablets, having hardness suitable for being dissolved in the mouth and pleasant taste.

What is claimed is:

1. An oral dosage form consisting essentially of (1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:

(a) 9 mg of budesonide;

(b) hydroxypropyl cellulose; and

(c) magnesium stearate, stearic acid, or a mixture thereof;

and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides an $AUC_{0\text{-}infinity}$ of said budesonide in said human of about 16431.2±10519.8 (pg)×(h)/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.

2. The oral dosage form of claim **1**, wherein said matrix further comprises lecithin.

3. The oral dosage form of claim **1**, wherein said matrix further comprises silicon dioxide.

4. The oral dosage form of claim **1**, wherein said matrix comprises magnesium stearate and further comprises starch or a starch derivative.

5. The oral dosage form of claim **4**, wherein said matrix comprises starch.

6. The oral dosage form of claim **4**, wherein said matrix comprises a starch derivative.

7. The oral dosage form of claim **1**, wherein said matrix comprises magnesium stearate, and further comprises lecithin, silicon dioxide, and starch or a starch derivative.

8. The oral dosage form of claim **1**, wherein said gastro-resistant coating comprises acrylic acid polymer, methacrylic acid polymer, or a mixture thereof.

9. The oral dosage form of claim **4**, wherein said wherein said gastro-resistant coating comprises acrylic acid polymer, methacrylic acid polymer, or a mixture thereof.

10. The oral dosage form of claim **7**, wherein said wherein said gastro-resistant coating comprises acrylic acid polymer, methacrylic acid polymer, or a mixture thereof.

11. An oral dosage form consisting essentially of (1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:

(a) 9 mg of budesonide;

(b) hydroxypropyl cellulose; and

(c) magnesium stearate, stearic acid, or a mixture thereof;

and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides a C_{max} of said budesonide in said human of about 1348.8±958.8 pg/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.

12. The oral dosage form of claim **11**, wherein said matrix further comprises lecithin.

13. The oral dosage form of claim **11**, wherein said matrix further comprises silicon dioxide.

14. The oral dosage form of claim **11**, wherein said matrix comprises magnesium stearate and further comprises starch or starch derivative.

15. The oral dosage form of claim **14**, wherein said matrix comprises starch.

16. The oral dosage form of claim **14**, wherein said matrix comprises a starch derivative.

17. The oral dosage form of claim **11**, wherein said matrix comprises magnesium stearate and further comprises lecithin, silicon dioxide, and starch or a starch derivative.

18. The oral dosage form of claim **11**, wherein said gastro-resistant coating comprises acrylic acid polymer, methacrylic acid polymer, or a mixture thereof.

19. The oral dosage form of claim **14**, wherein said wherein said gastro-resistant coating comprises acrylic acid polymer, methacrylic acid polymer, or a mixture thereof.

20. The oral dosage form of claim **17**, wherein said wherein said gastro-resistant coating comprises acrylic acid polymer, methacrylic acid polymer, or a mixture thereof.

21. A method of treating a human subject with ulcerative colitis, comprising administering to said human subject an oral dosage form consisting essentially of